Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

Selenium and vitamin E supplements have mixed effects on prostate cancer risk and may not be beneficial for everyone.

Finasteride for hair loss may increase the risk of certain cancers and has side effects; better regulation and education on its use are needed.

Androgen deprivation therapy for prostate cancer can cause sexual, physical, and psychological side effects, and doctors should manage these carefully.

Male hormones like testosterone may make COVID-19 worse, and testing for sensitivity to these hormones could help predict how severe a patient's symptoms might be. Treatments that reduce these hormones are being explored.

Finasteride is safe for hair loss treatment and doesn't increase high-grade prostate cancer risk.

A new compound was effective for imaging prostate cancer in rats.

Early baldness in men may indicate a higher risk of prostate cancer.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.

Scientists created iodinated arylhydantoins and arylthiohydantoins that could potentially be used for imaging prostate cancer. Some versions with specific side-chains showed high potential for this use.

Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.

Heavy metals like arsenic, cadmium, and lead can increase cancer risk and worsen outcomes.

5α-reductase inhibitors, like finasteride and dutasteride, effectively treat BPH, male baldness, and hirsutism, with potential for acne and prostate cancer prevention.

Hormones and genetics play key roles in male and female baldness, which can affect mental health and may be linked to other health issues.

The study found that androgen receptors in skin cells mainly affect the focal adhesion pathway and control the caveolin-1 gene, with implications for new treatments for related diseases.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

The document concludes that better research methods are needed in men's sexual health to provide stronger evidence and improve patient care.

Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.

The conclusion is that individualized treatment and proper medication use are crucial in men's health, with specific recommendations for ED, BPH, and prostate cancer management.

An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.

Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.

Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.

Aging men face unique health issues like erectile dysfunction, prostate problems, and baldness.

Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.